“This is a natural place for a platform proof-of-concept, because monoclonal antibodies against CD38 have been approved for the indication, and anti-CD3 antibodies have been shown to redirect ...

A recent Phase II trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce ...

Adding isatuximab, an anti-CD38 monoclonal antibody, to bortezomib, lenalidomide, and dexamethasone (VRd) may improve outcomes in transplant-ineligible patients with multiple myeloma. New research ...

One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

Paris: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) ...